Simply Wall St.8d agobullish
Generate Biomedicines (GENB) Stock Looks Fully Priced On Its 17% JumpNews
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
102last 24h
3125last 7d
511● bullish (7d)
311● bearish (7d)
227publishers
International Business Times10d agoneutral
Anthropic Announced New Achievements in Drug Research and Lab Work. An Expert Says AI is 'Changing the Medical Field.'MT Newswires11d agoneutral
Anthropic Says Claude Helped Generate 35,000 Drug Designs, Cut Drug Development WorkloadsGlobeNewswire17d agoneutral
Generate Biomedicines to Participate in November Investor ConferencesPharmaceutical Technology25d agoneutral
Zealand Pharma pens $1.2bn AI obesity drug discovery pact with GeneratePR Newswire26d agoneutral
Prologue Medicines Appoints Stephen Harrison, Ph.D., as Chief Scientific OfficerSimply Wall St.74d agoneutral
Generate Biomedicines (GENB) Stock Looks Pricey On Book Value Yet Strong On ReturnsThe Wall Street Journal101d agoneutral
Jersey Mike’s Is the Latest Stock Slide in Trading Debuts This YearMotley Fool124d agoneutral
Cathie Wood Likes That New Stock Smell: 3 IPO Stocks She Bought on MondayInsider Monkey138d agoneutral
Morgan Stanley Maintains an Overweight Rating on Generate Biomedicines, Inc. (GENB)Simply Wall St.160d agoneutral
A Look At Generate Biomedicines (GENB) Valuation As Shares Soften After Recent GainsMotley Fool161d agoneutral
A New $21 Million Position Signals Confidence in This Post-IPO Drug Developer